Clinical Trial Update: VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome [Phase 3]

View source ↗

Summary

The VISTA-16 Phase 3 trial evaluating short-term A-002 treatment in acute coronary syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• A-002

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Acute Coronary Syndrome | Phase 3 | Status: TERMINATED